SCHEMBL3721188

SCHEMBL3721188

COc1cccc(/C=C/C=C2CCN(c3nc(C)ccc3[N+](=O)[O-])CC2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 5/20 0.44
FBP1 P09467 1/20 0.43
ALDH1A1 P00352 5/20 0.43
CYP3A4 P08684 1/20 0.42
MAPT P10636 8/20 0.42
MAPK1 P28482 3/20 0.42
LMNA P02545 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAOA P21397 1/20 0.40
COMT P21964 1/20 0.40
CYP19A1 P11511 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
EGFR P00533 1/20 0.37
ERBB2 P04626 1/20 0.37
HTT P42858 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
NFE2L2 Q16236 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3721190 1.00 GRM5 (0.44) GRM5FBP1ALDH1A1CYP3A4MAPT
SCHEMBL3713971 0.89 GRM5 (0.45) GRM5FBP1ALDH1A1CYP3A4MAPT
SCHEMBL3771322 0.89 GRM5 (0.45) GRM5FBP1ALDH1A1CYP3A4MAPT
SCHEMBL3719860 0.88 GRM5 (0.47) GRM5FBP1ALDH1A1CYP3A4MAPT
SCHEMBL3775701 0.88 GRM5 (0.47) GRM5FBP1ALDH1A1CYP3A4MAPT
SCHEMBL3773523 0.87 GRM5 (0.47) GRM5FBP1ALDH1A1CYP3A4MAPT
SCHEMBL3766932 0.87 GRM5 (0.45) GRM5FBP1ALDH1A1CYP3A4MAPT
SCHEMBL3711478 0.87 GRM5 (0.47) GRM5FBP1ALDH1A1CYP3A4MAPT
SCHEMBL3710206 0.87 GRM5 (0.45) GRM5FBP1ALDH1A1CYP3A4MAPT
SCHEMBL3775736 0.86 GRM5 (0.49) GRM5ALDH1A1CYP3A4MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2393780-A1 HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS Recordati Ireland Limited (IE) 2011-12-14 EP claimed
US-20100317630-A1 NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2010-12-16 US claimed
WO-2010089119-A1 HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2010-08-12 WO claimed
US-20100317630-A1 NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317630-A1 NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS GRM5, GRIK5, HRH2 GRM5 1/4885FBP1 1248/4885ALDH1A1 2176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.